Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 25 of 3439 for:    Facility

TasP in Correctional Facilities

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02946762
Recruitment Status : Completed
First Posted : October 27, 2016
Last Update Posted : March 13, 2019
Sponsor:
Collaborator:
Department for International Development, United Kingdom
Information provided by (Responsible Party):
University of North Carolina, Chapel Hill

Brief Summary:
At correctional facilities in Zambia and South Africa, a cross-sectional study design will be used to characterize the full continuum of integrated HIV/TB care under Treatment as Prevention (TasP), and will enrich this approach by: 1) using individual-level cohort data for HIV-infected inmates to assess ART uptake under TasP/Universal Test and Treat (UTT), as well as 6-month virological suppression and retention in care for inmates initiating ART; and 2) mixed methods to identify health-system, corrections-related socio-cultural and individual-inmate barriers to and facilitators of TasP/UTT to refine TasP implementation; and 3) conducting a retrospective chart review using routine data from Ministry of Health registers to reconstruct an approximate HIV and TB cascade for all inmates (HIV-infected and HIV-uninfected) at 3 and 12 months into TasP/UTT implementation.

Condition or disease Intervention/treatment Phase
HIV Tuberculosis Other: Test and treat Not Applicable

Detailed Description:

Treatment as Prevention (TasP) offers promise to: (1) prevent HIV transmission among incarcerated populations; and (2) improve inmate health and tuberculosis control through provision of immediate ART using a "universal test and treat" (UTT) approach.

Increased uptake of routine HIV counseling and testing (HCT) services will be encouraged and currently available ART care will be augmented by offering immediate ART initiation to all HIV-infected inmates not already on ART (after screening for TB and kidney disease) regardless of CD4 count. In this way, the study will promote universal HCT and ART access.

Existing, routine service delivery platforms operated by the MOH and Zambia

Corrections Service will be strengthened in hopes of achieving the following:

  1. Universal HIV testing within 2 months of facility entry and annually for all current inmates
  2. Clear integration of TB screening and treatment within HIV care services
  3. Scaling-up inmate peer supporters and support groups to promote ART adherence
  4. Strengthened systems for providing integrated TB/HIV care in correctional settings
  5. Improved continuity of care for prisoners initiating ART

The following study-specific procedures will be carried out:

  • ART will be initiated following clinical and laboratory assessment according to local guidelines.
  • All inmates with newly diagnosed or previously documented HIV infection will be offered immediate ART regardless of CD4+ count or WHO clinical stage. A clinical assessment, including TB screening, and testing of serum creatinine will be completed, per Zambian national guidelines, prior to starting a standard ART regimen, which in Zambia is efavirenz plus lamivudine/ emtricitabine and tenofovir.
  • A study specific follow-up visit, aligned with the routine HIV care schedule, for all inmates identified as HIV-infected will occur:
  • Study nurses will support blood sample collection for HIV-1 viral load monitoring at the single study follow-up visit for all participants initiating ART under TasP. The planned follow-up visit will be scheduled to occur at 6 months following ART initiation. However, if a high recidivism rate and loss to follow-up prior to 6 months on treatment is observed, the study follow-up visit may be moved up to 3 months.

Study data collection will augment existing routine data collection mechanisms and allow individual-level outcome ascertainment regarding uptake of ART under TasP, as well as 6-month retention in care and virological suppression.

Standardized questionnaires and in-depth interviews will be conducted with inmate participants enrolled under Objective 1. To assess systems-level issues, in-depth interviews will also be conducted with a purposive sample of correctional staff and health care workers.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 419 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Health Services Research
Official Title: Z 31501 - Treatment as Prevention (TasP) in Correctional Facilities in Zambia and South Africa
Actual Study Start Date : February 1, 2016
Actual Primary Completion Date : March 31, 2018
Actual Study Completion Date : March 31, 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
Universal Test and Treat
All incarcerated individuals with HIV infection will receive antiretroviral therapy (ART) by test and treat.
Other: Test and treat
All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.




Primary Outcome Measures :
  1. Proportion of inmates with HIV-infection who were assessed for and offered ART initiation under TasP/UTT [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Proportion of all HIV-infected inmates starting ART who are retained on ART among those who remain in the study facility [ Time Frame: 2 years ]
  2. Proportion of inmates on ART with an HIV RNA <40 c/mL at 6 months of ART [ Time Frame: 6 months ]
  3. Proportion of HIV-infected inmates with TB diagnosis who initiate anti-TB therapy under TasP/UTT [ Time Frame: 2 years ]
  4. Proportion of inmates on ART with an HIV RNA <40 c/mL at 12 months of ART [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Previously known or newly diagnosed HIV-infected inmates
  • Not on ART
  • No documented release date within 30 days of enrollment
  • Incarcerated in an adult correctional ward at one of the three study sites.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02946762


Locations
Layout table for location information
Zambia
Lusaka Central Corrections ART Clinic
Lusaka, Zambia
Sponsors and Collaborators
University of North Carolina, Chapel Hill
Department for International Development, United Kingdom
Investigators
Layout table for investigator information
Principal Investigator: Michael Herce, MD, MPH University of North Carolina, Chapel Hill

Layout table for additonal information
Responsible Party: University of North Carolina, Chapel Hill
ClinicalTrials.gov Identifier: NCT02946762     History of Changes
Other Study ID Numbers: 15-1473
First Posted: October 27, 2016    Key Record Dates
Last Update Posted: March 13, 2019
Last Verified: March 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by University of North Carolina, Chapel Hill:
HIV
TB
Antiretroviral Treatment
Anti-tuberculosis Treatment
HIV Counselling and Testing
Treatment as Prevention
Additional relevant MeSH terms:
Layout table for MeSH terms
Tuberculosis
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections